Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NV102
- Development stage
- Preclinical
- Lead developer
- NanoValent Pharmaceuticals
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NV102 is a preclinical-stage nano-antibody drug conjugate (nano-ADC) being developed by NanoValent Pharmaceuticals for the treatment of CD19-positive hematological malignancies, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The drug utilizes NanoValent's proprietary Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform, also referred to as Targeted NanoSpheres (TNS), to encapsulate the cytotoxic payload doxorubicin. By functionalizing the surface of these nanoparticles with an anti-CD19 antibody, NV102 specifically targets cancer cells expressing the CD19 antigen, facilitating the intracellular delivery of doxorubicin while potentially reducing the systemic toxicities associated with conventional chemotherapy. This technology was developed in collaboration with Children's Hospital Los Angeles (CHLA).
- Other names
- NV-102NV102NV 102doxorubicin-anti-CD19 HPLNdoxorubicin-anti-CD-19 HPLNdoxorubicin-anti-CD 19 HPLNdoxorubicin-anti-CD19 TNSdoxorubicin-anti-CD-19 TNSdoxorubicin-anti-CD 19 TNS
02
Targets
Beyond the preview
Go deeper on NV102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NV102.